In the context of lung cancer, the main ICIs include PD-1/PD-L1 (Programmed cell death protein 1/Programmed death-ligand 1) and CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) inhibitors. Here, CTLA4 is linked to lung cancer.